Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lehmann

Showing results (501-510 of 532) with videos related to

Pageof 54
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancerKe-Da Yu, Rui Zhu, Ming Zhan, et al.
Plos One|April 17, 2020
Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsetsOlga Y Korolkova, Sarrah E Widatalla, Diva S Whalen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2005
Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variationC Holmes, C Ballard, D Lehmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2013
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibitionKatherine E Hutchinson, Doron Lipson, Philip J Stephens, et al.
Breast Cancer Research : BCR|August 9, 2014
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitorsBrian D Lehmann, Joshua A Bauer, Johanna M Schafer, et al.
Oncotarget|May 15, 2015
Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancerAndrew J Wilson, Oluwole Fadare, Alicia Beeghly-Fadiel, et al.
Nature Communications|November 2, 2021
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypesBrian D Lehmann, Antonio Colaprico, Tiago C Silva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2025
Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast CancerPaula I Gonzalez-Ericsson, Nisha Unni, Komal Jhaveri, et al.
Plos Computational Biology|August 6, 2016
Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer CellsRuth Merkle, Bernhard Steiert, Florian Salopiata, et al.
American Journal of Respiratory and Critical Care Medicine|November 6, 2023
Loss of p73 Expression Contributes to Chronic Obstructive Pulmonary DiseaseBradley W Richmond, Clayton B Marshall, Jessica B Blackburn, et al.
Pageof 54

Showing results (501-510 of 532) with videos related to

Sort By:
Pageof 54
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2013
Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancerKe-Da Yu, Rui Zhu, Ming Zhan, et al.
Plos One|April 17, 2020
Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsetsOlga Y Korolkova, Sarrah E Widatalla, Diva S Whalen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 19, 2005
Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variationC Holmes, C Ballard, D Lehmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2013
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibitionKatherine E Hutchinson, Doron Lipson, Philip J Stephens, et al.
Breast Cancer Research : BCR|August 9, 2014
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitorsBrian D Lehmann, Joshua A Bauer, Johanna M Schafer, et al.
Oncotarget|May 15, 2015
Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancerAndrew J Wilson, Oluwole Fadare, Alicia Beeghly-Fadiel, et al.
Nature Communications|November 2, 2021
Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypesBrian D Lehmann, Antonio Colaprico, Tiago C Silva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2025
Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast CancerPaula I Gonzalez-Ericsson, Nisha Unni, Komal Jhaveri, et al.
Plos Computational Biology|August 6, 2016
Identification of Cell Type-Specific Differences in Erythropoietin Receptor Signaling in Primary Erythroid and Lung Cancer CellsRuth Merkle, Bernhard Steiert, Florian Salopiata, et al.
American Journal of Respiratory and Critical Care Medicine|November 6, 2023
Loss of p73 Expression Contributes to Chronic Obstructive Pulmonary DiseaseBradley W Richmond, Clayton B Marshall, Jessica B Blackburn, et al.
Pageof 54